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Abstract
Hematopoietic stem cell or bone marrow transplantation (BMT) is one of the most promising and potentially
curative therapeutic options available for eligible patients with hematologic malignancies (HMs) or
leukemias. However, the nature and clinical course of HMs, specifically for patients undergoing BMT, are
associated with significant morbidity, symptomatology, healthcare service utilization, psychosocial and end
of life issues, and overall decreased quality of life. Early palliative care (PC) consultations and utilization for
patients with HMs have been shown to improve patient outcomes, satisfaction, and autonomy as well as
caregiver burden, shared-decision making, and holistic care management. Despite the complexity of care
and complications for patients with HM undergoing BMT, early PC interventions are systematically
underutilized and understudied in this population compared to patients with solid tumors or non-HMs.
Herein, the authors reviewed the current literature and knowledge to assess and report the perceptions and
barriers to early PC utilization in the care of patients with HMs undergoing BMT. Clinical and cultural
aspects of PC perceptions as well as current PC care models and potential directions for PC implementation
were reviewed to inform future research studies and clinical practice guidelines necessary for the
improvement of care and quality of life for HM patients undergoing BMT.
Categories: Pain Management, Oncology, Hematology
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Introduction And Background
Hematologic malignancies (HMs), or leukemias, are a common form of cancer in the United States, with over
60,000 estimated new cases in 2019 and over 400,000 individuals living with a form of leukemia in 2016 [1].
However, when compared to patients with solid tumors and malignancies, multiple studies across several
centers have found that patients with HMs receive suboptimal care near the end of life [2]. Patients with
HMs are more likely to experience a lower quality of life through higher rates of emergency room (ER) visits,
hospital or intensive care unit (ICU) admissions, hospital or ICU deaths, chemotherapy within the last 14-30
days of life, and aggressive care at the end of life. Importantly, patients with HMs compared to solid tumors
are significantly less likely to receive specialty palliative care (PC) interventions or consultations and die in
hospice care [2]. Previous studies have shown that early PC interventions in the oncologic patient
population are associated with increased patient agency and care participation, improved quality of life,
mood, satisfaction of care, and caregiver outcomes, as well as reductions in aggressive care at the end of life
[3]. PC interventions allow for establishing meaningful provider relationships earlier in the course of
treatment and for facilitating goals of care or advanced care planning discussions that may help reduce
aggressive treatment near the end of life and improve overall quality and satisfaction of care. However,
current guidelines in the National Comprehensive Cancer Network have not yet incorporated PC
interventions for patients with HMs. Furthermore, this remains an understudied topic that needs greater
insight as a majority of randomized clinical trials assessing the benefits and effects of PC interventions often
do not include patients with HMs [3]. Yet, some single-center studies both in the United States and in
Taiwan analyzing effects of early PC interventions for patients with HMs have demonstrated significant
reductions in ICU admission, chemotherapy usage, inappropriate cancer treatment, and cardiopulmonary
resuscitation (CPR) necessity in the final month of life [4]. A better understanding of the perceptions and
barriers of early PC interventions in the HM patient population is needed to begin implementing PC into
standard care practice to improve the quality of life for HM patients throughout their healthcare experience.
 For patients with HMs, one of the most important potential treatment options is hematopoietic cell
transplantation, also known as bone marrow transplantation (BMT). BMT potentially promotes remission or
even a cure for patients with HMs and provides the greatest probability of long-term survival for these
individuals [5]. Approximately 22,000 patients receive a BMT in the United States every year. However, the
subpopulation of patients with HMs who receive a BMT are the most likely to receive aggressive care at the
end of life due to the numerous complications and symptomatology pre-, peri-, and post-transplantation.
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Common symptoms include severe nausea, vomiting, and diarrhea, and common complications from
treatment include drug toxicity, bleeding, infection, mucositis, graft rejection, graft-versus-host disease, and
severe cardiac and/or respiratory complications [2]. Patients undergoing BMT have intense emotional,
psychosocial, and spiritual issues and considerations arising around the time of treatment [6]. Early PC
interventions are known to provide critical advice for symptom management and control throughout the
patient care experience while emphasizing goals of care and establishing advanced care decisions to
improve the quality of care according to patient preferences, values, and decisions. Thus, early PC
interventions may be of great benefit for HM patients undergoing BMT and aid in the important and difficult
transition points from curative to PC when necessary. Through improving physical and emotional symptom
control, timely PC interventions may also prevent medical crises and possibly lower rates of ER visits,
hospitalizations, and aggressive treatment for symptom control near the end of life for these patients.
However, there are limited numbers of studies analyzing the effects and benefits of early PC interventions
for patients with HMs undergoing BMT [7]. Furthermore, the intensive care and monitoring required during
the first few years post-BMT to manage symptoms, complications, morbidity, and mortality emphasize the
need for a better understanding of barriers and perceptions regarding early PC interventions for this patient
population. Improving this understanding can inform future studies and models on the necessary
considerations for implementing PC for HM patients undergoing BMT to improve health outcomes and
maximize quality of life and care.
Review
Clinical barriers and disparities
 While select studies have shown that implementing PC interventions early on in the care of patients with
HMs undergoing BMT has numerous positive outcomes and effects, important clinical barriers and
disparities have also been identified in these care models [4]. These different barriers and challenges for
early PC interventions can be divided into clinical or provider barriers, patient barriers, and logistical or
administrative barriers. One of the most common involves the difficulty of prognostication and optimistic
perspectives toward the assessment of patient outcomes. Several studies have demonstrated that both
providers and patients tend to overestimate prognosis and patient survival times [6]. Because of the
uncertainty of an exact prognosis and estimated recovery, this challenges and introduces hesitancy
toward the providers’ and patients’ shared decision on when to begin facilitating advanced-care discussions
and incorporating PC services. Furthermore, a major challenge revolves around both the providers’ and
patients’ hesitancy to discuss the transition point from curative treatment to palliative treatment. For
patients with HMs undergoing BMT specifically, short-term remissions are much more likely as compared to
patients with solid tumors [6]. This then creates significant difficulty in gauging when to involve the PC
team or when to engage hospice care. Because of these prognostic challenges of clinical judgment, several
studies have emphasized the need to move away from referrals to PC based on prognosis or life expectancy
and move toward basing the PC intervention on individual and family/caregiver needs [3]. Importantly, a
significant clinical or provider barrier is the general misperception of PC services being equated or
misconstrued as end-of-life care and, therefore, often thought of being implemented only when the patient
is dying, nearly dying, or decompensating and deteriorating [3].
In terms of barriers from the patient perception of PC, patients with HMs undergoing BMT may often prefer
to focus discussions with their providers on curative rather than palliative goals. As discussed later on, there
are significant cultural influences on the discussion of death and dying combined with misperceptions of PC
that may further contribute to patient barriers toward implementing PC early on in their care. Other
perspectives discussed by studies include the view that BMT patients perceive their treatment as high-risk
and, thus, that the nature of the treatment leads to expectations of suffering and symptom burden, so some
patients may not actively seek or feel the need to alleviate themselves from experiencing symptoms [6].
Finally, several logistic and administrative barriers toward early PC interventions in this patient population
center on resource constraints and the complexity of care organization/policy. For BMT patients specifically,
one key PC treatment to relieve certain symptoms is at-home transfusion support, which can be incredibly
difficult to perform and coordinate logistically [2]. As this often conflicts with policy and standards set in
place for hospice care, this is a clear example of logistical and policy challenges to provide the full range of
palliative support necessary for implementing early PC interventions for BMT patients [2]. Therefore, these
numerous barriers emphasize the need for clearly defining and deciphering common perceptions and
misperceptions of early PC interventions that may aid in the development of standardized care models to
improve the quality of life and care for patients undergoing BMT.
In PC, there are significant disparities between Whites and racial/ethnic minorities. The lack of literature on
the impact of culture on patients’ understanding of disease likely promotes this disparity [8]. People of
cultural minorities experience barriers to PC to the extent that minorities are more prone to receiving
treatment that does not coincide with their care goals [9]. A study by Mack et al. further demonstrates this
misalignment whereby despite having their wishes documented, African Americans are less likely than their
White counterparts to have their care goals met [10]. Regional differences in access to PC are another barrier
minorities face. Dumanovsky et al. report this to be the case for minorities in the Southern United States,
where inadequate access to PC may result from a regional lack of large hospitals, which are more likely to
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offer palliative services [11]. Also limited by geography is the ability to offer pain management, a core aspect
of PC. One study demonstrates that African Americans lack accessibility to pain medication because they
tend to live in areas where pharmacies do not supply opioids [12]. Despite these physical barriers and
disparities, an improved understanding of the influence of culture in PC will likely bridge the gap between
the care received by racial/ethnic minorities relative to Whites.
Cultural aspects
Culture is an important influence on patients’ preferences with respect to the processes, types of care
providers, and extent of care they would like to receive during their recovery [13]. One process includes the
extent to which patients want to be informed about their condition [14,15]. Certain Native American
cultures, for example, prefer not to speak about death, limiting their access to PC, and widening the disparity
relative to Whites [16]. Another key process includes shared decision-making. In the United States healthcare
setting, maintaining respect for patient autonomy is at the forefront of this discussion. However, persons of
different backgrounds and beliefs may not value autonomy highly during clinical decision-making [17].
Culture also influences whom patients desire to be named as their care providers. For instance, African
Americans more often emphasize the involvement of community leaders during end-of-life planning over
more formal discussions with their medical providers [18]. This likely stems from the long history faced by
African Americans of institutional abuse through slavery and mistreatment during research [13]. The extent
of care desired is another aspect that varies by cultural group. Studies have found that relative to Whites,
African Americans and Hispanics opt for more intensive end-of-life interventions [19]. For example, African
Americans and Hispanics are more likely to experience hospitalization, ICU admission, and advanced life-
sustaining therapies (CPR, intubation, mechanical ventilation, etc.) near the end of life as compared to
Whites [19]. Cain et al. note that although evidence-based generalizations may help with a foundation of
knowledge of different cultural/ethnic groups, it is important to still ask and discuss with patients about
their PC preferences [13]. There is no single pattern of preferences that each cultural group follows, but
rather there are in-group variations [19]. Because culture has a broad influence on patients' preferences of
processes, care providers, and breadth of treatment, further study is needed on the integration of culture
into PC and its role in influencing perceptions and misperceptions of PC.
Current care models
In a review of the current literature assessing the need for PC in HM and BMT patients, Epstein et al.
find that patients with HMs will likely benefit from increased access to PC [20]. However, the study also notes
the need for more work demonstrating the effects of various forms of PC delivery and implementation in the
HM population. Currently, there has only been one randomized trial, by El-Jawahri et al., demonstrating the
incorporation of PC into HM care [21]. Quality of life and symptom control including management of
psychological distress were significantly improved in this model that involved biweekly in-patient consults
by PC-trained physicians and nurse practitioners over a one-month period. Another study attempted to
maximize the distribution of limited PC services to the greatest number of critical HM patients by utilizing
PC “office hours” [22]. By offering this service within the hospital, hematologists were able to receive PC
support without requiring a formal PC consultation. Barriers to the entry of PC into hematology have been
discussed earlier in our review but include the misperception by hematologists that PC equates to end-of-
life care [23]. LeBlanc et al. also note that hematologists are less likely to manage patients with others, such
as PC physicians, due to the longitudinal nature of HM care, which contributes to more possessive physician
behavior toward patients. Many recommendations on the integration of PC into the management of patients
with HM being treated with BMT are extrapolated from the positive effects PC has demonstrated in the care
of patients with non-HMs. Well-studied care models from the non-HM aspect include establishing PC
services in cancer centers [24,25] and improving patient-centered communication and PC techniques in the
training of oncologists [26,27]. Further study is needed in demonstrating the efficacy of various PC models
in this subpopulation of HM patients undergoing BMT.
Potential niches
Relative to patients with metastatic non-HMs or solid tumors, patients with HMs experience a similar
number of symptoms with those symptoms causing an equal degree of distress [28]. Inadequate
management of this distress can negatively impact treatment outcomes and worsen quality of life [29].
Despite these findings, the role of PC in this population has been limited. Psychological symptoms, such as
anxiety and feelings of sadness, were reported in over 75% of patients in the Manitta et al. study, with these
symptoms presenting more severely in patients with HMs as compared to patients with metastatic non-HMs
[28]. This finding highlights the potential for PC as a mechanism to address the specific and more prominent
psychosocial needs of patients with HMs.
Another potential niche for PC in patients with HMs undergoing BMT comes in the form of improving
prognostic understanding. Awareness of one’s prognosis is especially important in the decision-making
process of patients with HMs who must consider significant interventions such as chemotherapy and BMT
[30]. El-Jawahri et al. describe that over 70% of both patients with HMs and their caregivers hold
inappropriately optimistic views of their prognosis relative to that of their oncologist. However, this study
also notes that when patients with HMs do maintain a prognostic outlook that is in line with their
oncologist’s views, they are more likely to have a worse symptom profile, experiencing more fatigue and
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depressive episodes. Temel et al. found in a study on a non-HM that early implementation of PC improved
prognostic understanding [25]. This supports the proposition that PC serves a key, adjunctive role to
standard oncological care in the management of difficult cases and should be explored further in patients
with HMs undergoing BMT [23].
Conclusions
Patients living with HMs and undergoing BMT are significantly more likely to receive aggressive care
toward the end of life and are more likely to have reduced quality of life near the end of life as compared to
patients with solid tumors. These findings are associated with the severity of treatment-related
complications of a BMT, which contributes to the symptomatology and aggressive treatments these patients
experience. Despite the considerable symptom burden, patients with HMs undergoing BMT are also less
likely to receive specialty PC referrals and are most often referred within the final months before the end of
life. Further efforts should be aimed at improving the understanding of perceptions from both patient and
provider perspectives regarding PC interventions to develop a care model integrating PC services with the
care of patients with HM undergoing BMT. Several studies have identified a number of barriers affecting the
implementation of PC referrals for this specific patient population. Some of the most commonly
encountered clinical barriers for both provider and patient include misperceptions of equating PC to end-of-
life care, overestimation or uncertainty of patient prognostication leading to challenges on deciding when to
implement PC interventions, hesitancy to transition from curative to palliative goals of care, and logistical
and organizational policy challenges of incorporating certain palliative treatments into practice. Similarly,
social barriers can be created when failing to incorporate patient culture into care goals, with culture
influencing key aspects of how patients view life, death, and treatment at the end of life. Due to the
aforementioned barriers to the practice of PC in this population of patients, few studies have examined the
efficacy of different care models of PC in patients with HM undergoing BMT. Despite the still-developing
practice of PC in this setting, potential niches for PC include decreasing symptom burden, notably
psychological ones, as well as improving patient’s prognostic understanding. The consideration of
important clinical and cultural PC barriers, lack of existing standardized PC models, and pursuit of potential
PC niches highlights the need for a better understanding of the perceptions and misperceptions of early PC
interventions in patients with HMs undergoing BMT to provide meaningful insight into improving the
quality of life and maximizing compassionate care for this resilient patient population. Improving research
and study on the implementation of specific early PC interventions and enhancing the perception of both
providers and patients toward the importance and benefits of PC use are warranted to continue improving
the care of patients with HMs undergoing BMT. 
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